
ASCO25: AI test shown to aid in prostate cancer treatment planning
New research has demonstrated that an AI-based test developed by US-based Artera can help identify which men with non-metastatic high-risk prostate cancer are most likely to benefit from being administered abiraterone. Abiraterone (Zytiga) is an androgen …